UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

            

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER

THE  SECURITIES EXCHANGE ACT OF 1934

For the Month of   January 2013            

File No.   000-54598

Stellar Biotechnologies Inc.

(Name of Registrant)

332 E. Scott Street, Port Hueneme, CA 93041

 (Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F __X__

FORM 40-F  ______

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ___

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.

(Registrant)

Dated:  January 23, 2013	By:  /s/  "Darrell Brookstein" Darrell Brookstein Director

Exhibits:

99.1

News Release dated January 15, 2013

99.2

News Release dated January 17, 2013

99.2

News Release dated January 22, 2013

January 15, 2013 13:43 ET

Stellar Biotechnologies' Shares Begin Trading on the OTCQB Market

PORT HUENEME, CA--(Marketwire - Jan 15, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), is very pleased to announce that it was listed for trading in U.S. yesterday on the OTCQB Market under the symbol SBOTF. (http://www.otcmarkets.com/stock/sbotf/quote)

OTCQB companies must be registered with and reporting to the SEC or a U.S. regulatory agency. Stellar has been fully reporting to the SEC since April 4, 2012; its regulatory filings are available on EDGAR in the U.S. (http://edgar.sec.gov/) as well as on SEDAR in Canada (www.sedar.com).

In addition, Stellar's stock became fully "DTC Eligible" last week, which facilitates trading of its shares electronically between brokerage firms, and market making of its shares in the U.S.

Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com

Corporate Profile and December 2012 Audio Investor Presentation:

http://stellarbiotechnologies.com/investors/corporate_profile/

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

Forward-Looking Statements

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Contact Information

•

Contacts:

Stellar Biotechnologies, Inc.

Darrell Brookstein

Executive VP, Corporate Development and Finance

Phone: 805 488 2800

Email: dbrookstein@stellarbiotech.com

Investor Relations:

MZ Group

Mark A. McPartland

Senior Vice President

Phone: 1 212-301-7130

Email: markmcp@mzgroup.us

Web: www.mzgroup.us

January 17, 2013 09:35 ET

Stellar Biotechnologies to Present at Nobel Financial Capital Markets Ninth Annual Equity Conference January 23, 2013

PORT HUENEME, CA--(Marketwire - Jan 17, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), today announced that Darrell Brookstein, the Company's Executive VP of Corporate Development & Finance will present at "NINE"; Noble Financial Capital Markets' Ninth Annual Equity Conference being held at the Hard Rock Hotel in Hollywood, Florida January 22-23, 2013. Mr. Brookstein will discuss Stellar's unique investment merits as the only source for a renewable, sustainable and traceable supply of GMP grade KLH for large drug producers, and provide an overview of the Company's current growth initiatives.

Noble Financial Capital Markets Ninth Annual Equity Conference:

Location: The Hard Rock Hotel and Casino in Hollywood, Florida

Date: Wednesday, January 23, 2013

Time: 1:00PM EST

Webcast Information: At the time of the presentation, a live audio and high-definition video webcast of Stellar's presentation and a copy of the presentation materials will be available on the Company's website at www.stellarbiotech.com, or through the Noble Financial website at: www.noblefcm.com or www.nobleresearch.com/NINE/home.htm.

The Company recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on Stellar's website for 90 days following the event for future viewing.

To learn more about Stellar Biotechnologies and KLH please visit www.StellarBiotech.com and the KLH knowledge base site www.KLHSite.com

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

 

About Nobel Financial Capital Markets 9th Annual Equity Conference

Public company executive teams with an emphasis on healthcare, technology, defense, and new-media / entertainment sectors. Institutional investors from across North America. Detailed and personalized scheduling and organization. More information: please visit the website at http://www.nobleresearch.com/NINE/

Forward-Looking Statements

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Contact Information

•

Contacts:

Stellar Biotechnologies, Inc.

Darrell Brookstein

Executive VP, Corporate Development and Finance

Phone: 805 488 2800

Email: dbrookstein@stellarbiotech.com

Investor Relations:

MZ Group

Mark A. McPartland

Senior Vice President

Phone: 1 212-301-7130

Email: markmcp@mzgroup.us

Web: www.mzgroup.us

January 22, 2013 08:55 ET

Stellar Biotechnologies Pioneers Aquaculture Milestone in KLH Protein Manufacturing

Stellar Achieves First Independent System for Fully Sustainable KLH Production

PORT HUENEME, CA--(Marketwire - Jan 22, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company has successfully achieved a commercial-scale aquaculture system that sustains the complete life cycle of multiple generations of the Giant Keyhole Limpet (Megathura crenulata), the scarce marine source for Keyhole Limpet Hemocyanin (KLH).

Stellar has developed a controlled, land-based aquaculture system that supports the life cycle of the mollusk through all its stages and now, for the first time, boasts multiple generations producing commercial quantities of pharmaceutical grade KLH.

Stellar is the only company that can offer KLH obtained from sources and processes that are traceable, controlled, and sustainable. Other KLH suppliers are reliant on the small and sensitive, wild populations of Megathura crenulata and cannot offer KLH that meets Stellar Biotechnologies standards.

"This isn't just about increasing Stellar's KLH manufacturing leadership -- which we've clearly done," said Frank Oakes, Stellar President and CEO. "This is about controlling the lifecycle of the source animal, allowing Stellar to grow new generations of limpets spawned by parents that have never seen the ocean, thus ensuring that the pharmaceutical industry has ample supply of GMP grade KLH, made under controlled conditions, while protecting survival of a wild species."

Brandon Lincucum, Stellar Aquaculture Manager, said, "This is the culmination of more than ten years of highly-specialized development work involving a range of disciplines. We've set the benchmark for KLH manufacturing and we're proud to represent these new aquaculture and environmental milestones as well."

For more information or view investor webcast:

Visit www.StellarBiotech.com

For KLH knowledge base, visit www.KLHSite.com

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Contact Information

•

Contacts:

Stellar Biotechnologies, Inc.

Darrell Brookstein

Executive VP, Corporate Development and Finance

Phone: 805 488 2800

Email: dbrookstein@stellarbiotech.com

Investor Relations:

MZ Group

Mark A. McPartland

Senior Vice President

Phone: 1 212-301-7130

Email: markmcp@mzgroup.us

Web: www.mzgroup.us